Results

1–10 of 20 results for diabetic macular edema (DME)

Phase 2a Study of CU06-1004, an Oral Endothelial Dysfunction Blocker For the Treatment of Diabetic Macular Edema (DME)
Victor Hugo Gonzalez, MD
Annual Meeting Talks
2024
Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
Factors Associated With Fluctuations in Central Subfield Thickness in Patients With Diabetic Macular Edema Using 2 Clinical Trial Databases
Matthew Starr, MD
Annual Meeting Talks
2022
Angiopoietin-2 Signaling and Vascular Stability With Faricimab in Diabetic Macular Edema
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2022
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
John W. Kitchens, MD
Annual Meeting Talks
2022
Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results of the Phase 3 YOSEMITE and RHINE Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2022
Outcomes of Eyes Lost to Follow-up After Treatment With Intraocular and Periocular Steroid Injections
John W Hinkle, MD
On Demand Cases, Courses, and Papers
2021
Real-World Impact of Early Treatment With Intravitreal Dexamethasone Implant in DME in US Clinical Practice: Outcomes From the Vestrum Database
Roger A. Goldberg, MD, MBA
On Demand Cases, Courses, and Papers
2021
Treatment Patterns and Vision Changes in Anti-VEGF Refractory Diabetic Macular Edema After Dexamethasone Implant in US Clinical Practice
Yasha S Modi, MD
On Demand Cases, Courses, and Papers
2021
Baseline Factors Influencing Diabetic Macular Edema (DME) Resolution After Intravitreal Aflibercept Injection (IAI) or Laser Treatment in VISTA/VIVID
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2021